Sitaxentan
Sitaxentan (marketed under the brand name Thelin) was an oral medication used to treat pulmonary arterial hypertension (PAH). It belonged to a class of medications known as endothelin receptor antagonists, which help to relax the blood vessels in the lungs, making it easier for the heart to pump blood through them.
Mechanism of Action
Sitaxentan worked by selectively blocking the endothelin receptor type A (ET_A), which is predominantly responsible for the vasoconstrictive and proliferative effects of endothelin-1 (ET-1), a potent vasoconstrictor. By inhibiting this receptor, sitaxentan reduced pulmonary vascular resistance and improved cardiac output in patients with PAH.
Clinical Use
Sitaxentan was approved for the treatment of pulmonary arterial hypertension in several countries, including Canada, Australia, and the European Union. It was indicated for use in patients with Class II or III symptoms of PAH to improve exercise capacity and delay clinical worsening. However, it was not approved for use in the United States.
Adverse Effects
The use of sitaxentan was associated with several potential adverse effects, including liver enzyme elevations, peripheral edema, nasal congestion, and anemia. Due to the risk of liver toxicity, patients on sitaxentan required regular monitoring of liver function tests.
Withdrawal from Market
In December 2010, Pfizer, the manufacturer of sitaxentan, voluntarily withdrew the drug from the market due to concerns over its safety profile, particularly the risk of potentially fatal liver injury. The decision to withdraw sitaxentan was based on a review of ongoing clinical trials and post-marketing reports.
Impact on Treatment of PAH
The withdrawal of sitaxentan from the market left a gap in the treatment options available for PAH patients. However, other endothelin receptor antagonists, such as bosentan and ambrisentan, continue to be used in the management of PAH, offering alternative treatment options for patients affected by this condition.
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD